Lumasiran
id:
lumasiran-227-3490403
title:
Lumasiran
text:
Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1). The most common side effects include injection site reactions and abdominal pain. Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) that reduces levels of glycolate oxidase (GO) enzyme by targeting the HAO1 messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. Decreased GO enzyme levels reduce the amount of available glyoxylate, a subs
brand slug:
wiki
category slug:
encyclopedia
description:
Medication for the treatment of primary hyperoxaluria type 1
original url:
https://en.wikipedia.org/wiki/Lumasiran
date created:
2020-10-18T04:39:50Z
date modified:
2024-09-15T05:27:59Z
main entity:
{"identifier":"Q100692768","url":"https://www.wikidata.org/entity/Q100692768"}
image:
fields total:
13
integrity:
15